Kanwal Pratap Singh Raghav

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study

Funda Meric‐Bernstam, Muralidhar Beeram, Erika Hamilton et al. · The Lancet Oncology · 2022 · 164 citations · Full text

Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer

Kanwal Pratap Singh Raghav, Jonathan M. Loree, Jeffrey S. Morris et al. · JCO Precision Oncology · 2019 · 126 citations

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study

Marwan Fakih, Kanwal Pratap Singh Raghav, David Chang et al. · EClinicalMedicine · 2023 · 92 citations · Full text

Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials

Michael J. Overman, Van K. Morris, B. Kee et al. · Annals of Oncology · 2016 · 26 citations · Full text

Cancer Detection, Cancer Screening, Patient Selection +10

1758O Neoadjuvant pembrolizumab in localized/locally advanced solid tumors with mismatch repair deficiency

Kaysia Ludford, Kanwal Pratap Singh Raghav, Michelle Murphy et al. · Annals of Oncology · 2021 · 17 citations

Medicine, Immunology, Pathology +7